Donate Toggle Menu

The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer’s Sutent(R) (sunitinib malate) versus Sutent(R) alone.

 

Read the full article online

.